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ABSTRACT Doxorubicin (DOX) is used for treating various cancers. Its clinical use is, however, limited by its dose-limiting
cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy still remains unknown. The goals were to investigate
the molecular mechanism of DOX-induced cardiomyopathy and cardioprotection by mitoquinone (Mito-Q), a triphenylphospho-
nium-conjugated analog of coenzyme Q, using a rat model. Rats were treated with DOX, Mito-Q, and DOX plus Mito-Q for 12
weeks. The left ventricular function as measured by two-dimensional echocardiography decreased in DOX-treated rats but
was preserved during Mito-Q plus DOX treatment. Using low-temperature ex vivo electron paramagnetic resonance (EPR),
a time-dependent decrease in heme signal was detected in heart tissues isolated from rats administered with a cumulative
dose of DOX. DOX attenuated the EPR signals characteristic of the exchange interaction between cytochrome c oxidase
(CcO)-Fe(III) heme a3 and CuB. DOX and Mito-Q together restored these EPR signals and the CcO activity in heart tissues.
DOX strongly downregulated the stable expression of the CcO subunits II and Va and had a slight inhibitory effect on CcO subunit
I gene expression. Mito-Q restored CcO subunit II and Va expressions in DOX-treated rats. These results suggest a novel
cardioprotection mechanism by Mito-Q during DOX-induced cardiomyopathy involving CcO.INTRODUCTION
Doxorubicin (DOX), an anthracycline quinone antibiotic, is
widely used in the treatment of several cancers, including
breast cancer, Hodgkin’s disease, and leukemia (1,2).
However, its clinical use is limited by a dose-dependent,
acute and chronic cardiotoxicity that is cumulative and irre-
versible (3–5). The cardiac dysfunctions, i.e., irreversible
congestive heart failure, arrhythmias, and cardiomyopathy,
are the major cause of mortality in cancer patients treated
with DOX (6,7). Heart problems in DOX-treated cancer
patients do not manifest until several years after cessation
of chemotherapy (8,9). Children treated for leukemia with
DOX develop heart conditions (e.g., impaired left ventricular
contractility and late congestive heart failure) many years
after DOX chemotherapy (10,11). Estimates indicate that
children who undergo DOX chemotherapy are nearly eight
times more susceptible to develop heart problems later in
life (11). The exact mechanism of DOX-induced belated
cardiotoxicity still remains unknown, although multiple
mechanisms have been proposed, including oxidative stress,
mitochondrial DNA damage, intracellular calcium overload,
cytokine release, and disturbance of myocardial adrenergic
function (12,13).
Recent research shows that DOX treatment induces
apoptosis in myocytes and endothelial cells (14–16).
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0006-3495/09/02/1388/11 $2.00Apoptosis in myocardium eventually leads to cardiomyop-
athy due to a systematic reduction in the number of cardio-
myocytes (17). DOX also causes acute toxicity, including
endothelial dysfunction (18). The target organ of DOX
toxicity is the myocardium enriched with mitochondria. Prior
reports suggest that one of the reasons why heart muscle is
more susceptible to oxidant-induced damage is due to the
presence of low levels of antioxidant enzymes, such as cata-
lase, in myocytes (19,20). DOX accumulates over time into
mitochondria. The intramitochondrial concentration of
DOX was reported to be nearly two orders of magnitude
higher than its extracellular concentration in the culture media
(21,22). Thus, at clinically relevant plasma concentrations
(0.5-1 mM), the intramitochondrial concentration of DOX
should be ~50-100 mM. The selective toxicity of DOX to
the heart was attributed to the selective damage to cardiac
mitochondria (20).
Previously it has been shown that coenzyme-Q (Co-Q)
administration prevents the onset and progression of DOX-
induced cardiomyopathy (23). Co-Q administration resulted
in improved EKG changes and survival rates (23). It was
proposed that the lipophilic aglycone metabolite of DOX
presumably penetrates the inner membrane, displacing
Co-Q, which leads to the acute rise in the plasma Co-Q levels
in patients during DOX chemotherapy. Although numerous
antioxidant therapies have previously been developed to
combat DOX toxicity (24), most of these agents were not
particularly effective. In addition, these antioxidants were
not specifically targeted to mitochondria of cells. Recent
doi: 10.1016/j.bpj.2008.10.042
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specifically target mitochondria (25–27). Antioxidants such
as vitamin-E and coenzyme-Q were coupled to the triphenyl-
phosphonium cation, and the resulting compounds (Mito-E
and Mito-Q) were preferentially taken up by the mitochon-
dria (26,27). The driving force responsible for mitochondrial
accumulation of lipophilic triphenylphosphonium cations is
the large membrane potential of 150-180 mV (negative
inside) across the mitochondrial inner membrane (26,27).
Mito-Q was shown to accumulate 50- to 100-fold within
mitochondria (27).
To more closely mimic DOX-induced cardiomyopathy in
the clinic, lower doses of DOX were chronically administered
to Sprague-Dawley rats once a week (2.5 mg/kg), and 2D
echocardiography was performed to assess the morphologic
and functional changes in the left ventricle. This model is
consistent with the previously established model of chronic
DOX-induced cardiomyopathy (28). The cardiac tissues are
abundant in electron paramagnetic resonance (EPR) active
binuclear and mononuclear Cu, Fe centers and various bi-,
tri- and tetranuclear Fe-S clusters (29) (Fig. 1). In this study,
we have examined levels of mitochondrial cytochrome c
oxidase subunits and electron transfer iron sulfur clusters
using an established rat model that mimics the lower doses
of DOX used to study DOX-induced cardiomyopathy in the
clinic. Treatments with DOX or DOX plus Mito-Q, a coen-
zyme-Q analog, were compared to assess the cardioprotective
effects of Mito-Q. The electronic states of cytochrome
c oxidase components were monitored by ex vivo low-
temperature (liquid helium) X-band EPR.
Our data revealed that DOX treatment alters exchange
coupling between high spin heme a3 and CuB in complex
IV, but leaves iron sulfur clusters unaffected. After prolonged
treatment with DOX, levels of subunits II and Va were
decreased relative to other cytochrome c oxidase (CcO)
subunits. Mito-Q attenuated the effects of DOX treatment.
MATERIALS AND METHODS
Materials
DOX hydrochloride, rotenone, diethylenetriaminepentaacetic acid, cyto-
chrome c, antimycin, EDTA, tris, ubiquinone-1, potassium cyanide, and
NADH were purchased from Sigma Chemical (St. Louis, MO). Mitoquinone
(Mito-Q10) was synthesized according to the published method with some
modifications (30). A major difference between our procedure and the pub-
lished procedure (30) is the synthesis of the intermediate bromoidebenone
from idebenone (Fig. S1 in the Supporting Material). The published route
for bromoidebenone involved the use of carbon tetrabromide and triphenyl
phosphine. Bovine CcO was obtained as a gift from Dr. Helmut Beinert
(Department of Biochemistry, University of Wisconsin, Madison).
Animal care and treatment protocols
All animal procedures were approved by the Medical College of Wisconsin
Institutional Animal Care and Use Committee, and the investigation
conforms to the Guide for the Care and Use of Laboratory Animals, pub-
lished by the US National Institutes of Health (NIH Publication No. 85–23,revised 1996). Male Sprague-Dawley rats weighing 250-260 g were used
because females may possess cardiac protective effects because of estrogen,
along with increased levels of telomerase activity, which could increase the
tissue regeneration capacity. Animals were housed in the Biocontainment
Suite and had free access to a diet consisting of normal rat chow (Harlan
Teklad, Madison, WI) and water ad libitum.
Animals were randomly assigned to four different treatment groups:
control (n ¼ 16), DOX (n ¼ 11), DOX plus Mito-Q (n ¼ 12), and Mito-
Q (n ¼ 19) (Fig. S2). In experiment I, rats were injected intravenously
2.5 mg/kg per week with doxorubicin hydrochloride dissolved in saline,
and control groups received the same volume of saline (0.9% sodium chlo-
ride solution). In experiment II, DOX (2.5 mg/kg per week) and Mito-Q
(5.0 mg/kg by intraperitoneal injection, twice a week) were given. In exper-
iment III, Mito-Q alone (5.0 mg/kg) was administered under similar condi-
tions. During this period, rat body weight and echocardiograms were obtained
at baseline, 4, 8, 10 and 12 weeks after initiation of treatment. After 4, 8, 10
and 12 weeks of treatment, animals were euthanized with an intraperitoneal
injection of sodium pentobarbital (90 mg/100 g body weight). The heart
was excised immediately and stored in liquid nitrogen for histology and
EPR measurements. Tissues for histology were fixed in zinc-formaldehyde
solution (Fisher Scientific, Pittsburgh, PA).
EPR measurements
The X-band EPR of cardiac tissues were recorded at liquid helium tempera-
tures on a Bruker E500 ELEXYS spectrometer with 100 kHz field modulation,
equipped with an Oxford Instrument ESR-9 helium flow cryostat and a DM-
0101 cavity. For EPR measurements, heart tissues were excised and immersed
in liquid nitrogen, minced to appropriate sizes under liquid nitrogen, and then
transferred to a four mm quartz EPR tube (Wilmad-Lab Glass, Buena, NJ).
The heart tissue weight in each EPR experiment was ~0.3 g. The tissue
packing factor was not perceived to be a major problem, as reloading of tissues
in the same EPR tube (with a different packing) resulted in EPR spectra with
a 5% variation in signal intensity. Bovine heart CcO (30 mM) present in 10%
dodecyl maltoside containing 100 mM potassium/HEPES, pH 7.0, was used
as a standard. Spectrometer conditions were as follows: microwave frequency,
9.635 GHz; modulation frequency, 100 kHz; modulation amplitude, 10 G;
receiver gain, 85 dB; time constant, 0.01 s; conversion time, 0.08 s; sweep
time, 83.9 s. EPR spectra were obtained over the temperature range 4-50 K
using an incident microwave power of 5 mW and a modulation amplitude
of 10 G. The spectrometer was calibrated with the radical 1,1-diphenyl-2-pic-
rylhydrazyl, exhibiting an EPR signal centered at g ¼ 2.0036.
EPR simulations
EPR spectra for an exchange coupled two-spin system were successfully
fitted using the spin Hamiltonian shown in Eq.1 in the ‘‘Results’’ section.
FIGURE 1 Mitochondrial respiratory chain iron-sulfur centers, cyto-
chromes, and active metal centers involved in the electron transport process.
(I) NADH dehydrogenase, (II) Succinate dehydrogenase, (III) Cytochrome c
reductase, and (IV) Cytochrome c oxidase.Biophysical Journal 96(4) 1388–1398
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ization of this equation with XSophe software. A matrix diagonalization
method was used to obtain the eigenvalues and eigenvectors. For a dinuclear
Fe(III) (heme a3) CuB(II) center that is antiferromagnetically coupled, where
S1 ¼ 5/2 and S2 ¼ 1/2, a 12  12 energy matrix was obtained when all
twelve spin transitions were included (i.e., (2S1 þ 1)  (2S2 þ 1) ¼ 12).
Microwave power saturation and variable temperature EPR spectra are
shown (Figs. S4 and S5).
Activities of NADH-quinone reductase (complex I),
CcO and aconitase
The activities of complex I were assayed as reported at 30C as a decrease of
absorption at 340 nm with 200 mM NADH and 100 mM ubiquinone-1 in the
presence of 1.5 mM KCN. The activity of CcO was measured spectrophotomet-
rically by following the oxidation of ferrocytochrome c at 550 nm (31). The
standard assay mixture contained the following: 0.25 M sucrose, 50 mM
Tris/Cl -(pH 8.0), 0.2 mM potassium EDTA, and the enzyme preparation (mito-
chondria ~10 mg protein/ml). Aconitase activity was determined spectrophoto-
metrically by monitoring the disappearance of cis-aconitate as reported (32).
Caspase activity measurements
The excised heart was washed in ice-cold Krebs-Henseleit buffer solution
containing NaCl 118 mM, KCl 4.75 mM, KH2PO4 1.19 mM, MgSO4
1.19 mM, CaCl2 2.54 mM, NaHCO3 25 mM, EDTA 0.5 mM, and glucose
11 mM and immediately frozen in liquid nitrogen. Frozen tissue was subse-
quently ground into a powder, using a mortar and pestle, and resuspended
with ice-cold lysis buffer (50 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM
DTT, 2 mM EDTA, 2 mM EGTA, Triton X-100, 0.1%) containing 1 mM
phenylmethylsulfonyl fluoride and 10 mg/ml aprotinin and leupeptin.
Homogenates were centrifuged at 14,000  g for 10 min and the superna-
tants were used. Proteins (100 mg) were diluted with the assay buffer
(50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT,
2 mM EDTA, 2 mM EGTA, Triton X-100, 0.1%, and incubated at 25C
with DEVD-pNA (acetyl Asp-Glu-Val-Asp paranitroanilide), ac-LEHD
pNA (acetyl Leu-Glu-His-Asp pNA), and ac-IETD pNA (acetyl-Ile-Glu-
Thr-Asp-pNA) as substrates (each 200 mM final concentration). The absor-
bance at 405 nm of the released pNA was monitored in a spectrophotometer
and quantitated using a suitable standard (33).
Immunoblot analysis for cytochrome c oxidase
subunit content
Proteins were subjected to electrophoresis on 15% polyacrylamide gels as
described by Kotamraju (33). The conditions for Western blot analysis and
immunodetection of proteins were the same as described previously (34).
Specific antibody interactions were tested by probing with monoclonal anti-
bodies to CcO subunits I, II, IV and Vb obtained from Mitosciences (Eugene,
OR). Secondary antibody was detected and quantitated by incubating the
membrane with West Femto Super Signal (Pierce, IL). Blots were quantified
with an Image Scanner STORM (Molecular Dynamics, Sunnyvale, CA).
Echocardiography
Transthoracic two-dimensional echocardiography (Vivid 7 Echocardiograph,
General Electric, Waukesha, WI) was performed with the use of a linear array
11 MHz transducer at baseline, 4, 8, 10, and 12 weeks on all animals anesthe-
tized by using 0.25 mg/kg medtomidine and 75 mg/kg ketamine. The chest of
the animal was shaved for the procedure. The parasternal short axis view at the
mid left ventricular level was used, verified by the presence of prominent
papillary muscles. B-mode 2-dimensional echocardiography was performed.
Offline analyses were performed using Echopac workstation (General Elec-
tric, Waukesha, WI). Myocardial radial strain, an intrinsic measure of
myocardial mechanics, was obtained using Q analysis software (GeneralBiophysical Journal 96(4) 1388–1398Electric, Waukesha, WI) as reported previously (31). Briefly, the endocardial
border was traced and the epicardial border was delineated manually. The
software automatically computes the radial strain (percent change of myocar-
dial segment length toward or away from the center of the heart in short axis
view) from six equidistant segments of the left ventricle. The global radial
strain was the average of the six segmental radial strains The data from rats
that survived >8 weeks were used for analysis.
Statistical analysis
For radial strain, repeated analyses of variance with treatment and time
as covariants was used (Sigmastat 3.5, Systat Software Richmond, VA).
For pairwise analysis, Holm-Sidak method was used. Significant p-value
was set at p ¼ 0.05.
RESULTS
Mito-Q administration prevents DOX-induced
cardiac dysfunction
Initially, the cardiac function after treatment with DOX, with
and without Mito-Q coadministration, was monitored by
physiological parameters and by 2D echocardiography. As
shown in Fig. S2, animals were divided into four groups.
After 10 weeks of DOX treatment, animals became weak
and lethargic and the skin color became pale as compared
to control rats. The most prominent feature in DOX-treated
animals was the development of an enlarged abdomen and
ascites after eight weeks of DOX treatment; postsacrifice,
a significant amount of peritoneal fluid was noted. In addition,
the body weight of the DOX-treated rats was significantly
lower than that of the control (Fig. 2). After 10 weeks of treat-
ment, the heart weight of DOX-treated rats was considerably
less than that of the control. In contrast, the body weight and
the heart weight of DOX plus Mito-Q treated rats were similar
to those of control and Mito-Q-treated rats. Prolonged treat-
ment with Mito-Q partially reversed the adverse side effects
caused by DOX administration (Fig. 2).
DOX treatment diminished myocardial function. Myocar-
dial strain is a measure of intrinsic myocardial mechanics
(31). Two-dimensional strain echocardiography serves as a
sensitive measure of myocardial dysfunction in both human
and rodent models and is superior to other conventional
measures of ventricular function. The administration of DOX
caused a reduction in cardiac function assessed by echocardiog-
raphy (31). There was a progressive reduction in global radial
strain starting at eight weeks after DOX treatment (Fig. 3).
Coadministration of Mito-Q prevented the progressive decline
in global radial strain seen with DOX treatment alone.
Ex vivo low temperature EPR spectra of control
heart tissues: Effects of DOX and DOX plus Mito-Q
To evaluate the status of redox-active components of heart
tissue, rats were sacrificed after defined treatment protocols.
As shown in Fig. S2, rats were sacrificed after 4, 8, 10, and
12 weeks of treatment protocols, and hearts were removed
and frozen for EPR analysis. The EPR spectra of control rat
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discernible signals are due to the high spin heme at g ¼ 6.0,
assigned to heme a3 (Fea3
3þCuB
1þ state of CcO), high spin
cytochrome c, and a trinuclear 3Fe-4S cluster signal at g ¼
2.015 (35). At a higher gain, other EPR absorptions were
noticeable (Fig. 4 A, dashed line). Based on spectral simula-
tions, the composite EPR spectrum was deconvoluted into
several different species (Fig. S3). As cardiac tissues are en-
riched in mitochondria, the signals arising from the binuclear
[2Fe-2S] cluster (N1), complex II or III, and three tetranuclear
[4Fe-4S] clusters (N2, N3 and N4) were also detected. The
EPR parameters obtained from computer simulations are in
agreement with those previously reported for complex I, II
and III iron-sulfur clusters (35). The spectrum (Fig. 4 A)
also consists of a low spin heme signal at gz ¼ 3.0 [heme a,
cytochrome c] and at gz¼ 3.9-3.2 (cyt-bH and cyt-bL), respec-
tively (36,37). The simulations of these signals were achieved
by using a large line width parameter, suggesting that these
absorptions are either a magnetically coupled system or that
there is strain broadening. The resonance at gz ¼ 2.16 was
assigned to a dinuclear CuACuA center of complex IV (38).
The CuACuA signal at g ¼ 2.02 was obscured by the strong
FIGURE 2 (A) Changes in the heart weights of rats after 12 weeks
of treatment with DOX, Mito-Q, and DOX plus Mito-Q. (B) Changes in
the body weights of rats undergoing DOX treatment as shown in Fig. S2.3Fe-4S signal. In addition, an EPR signal detected at
g ¼ 4.3 was tentatively attributed to a rhombic iron (III).
The experimental and simulated EPR spectra of authentic
CcO enzyme are shown in Fig. S6.
Fig. 4B shows the effect of DOX on the EPR spectra of heart
tissues with time. Heart tissues were isolated from rats after 4, 8,
10, and 12 weeks of DOX treatment. Initially, the EPR intensity
of the g ¼ 6 signal (assigned to heme a3 of CcO) after four
weeks of DOX treatment increased. Thereafter, the intensity
of this signal (g ¼ 6) decreased with increasing duration of
DOX treatment. However, the EPR signals (g¼ 2.013) corre-
sponding to the Fe-S clusters of complex I, II and III were not
significantly affected by DOX treatment under the same condi-
tions. In the presence of DOX and Mito-Q, the EPR signal
intensities at g ¼ 6 obtained from heart tissues after 4, 8, 10,
and 12 weeks of DOX treatment were similar to those obtained
from control tissues. These results suggest that a prolonged
treatment with DOX disrupts CcO in myocardial tissues and
that the protective effect of Mito-Q in DOX-treated rats could
be related to restoration of the signal intensity of heme a3 of
CcO in heart tissues (Fig. 4 C).
Effect of DOX and Mito-Q on exchange-coupled
resonances
Heme a3 and CuB sites are in close proximity, and thus
exhibit exchange coupling. Fig. 5 shows the EPR spectra
of control heart tissues obtained at a higher microwave
power. At low temperatures (¼ 10 K) and at a higher micro-
wave power (120 mW), the EPR signals at gz ¼ 3.0 arising
from the low spin Fe(III) of heme a and cytochrome c were
partially saturated for analysis of the exchange coupled reso-
nances. The exchanged coupled spectra were best simulated
(Fig. 5 B) based on the weak magnetic exchange interaction
between high spin Fe(III) heme and Cu(II) of CcO, described
by an effective spin-Hamiltonian involving an exchange
coupling tensor J (Eq. 1) (37):
bH ¼ hgbHbS þ DðbS2z  bS2=3Þ þ EðbS2x  bS2yÞiFe
þ gbHbSCuþ bSFe$J$bSCu (1)
where the first term represents the local spin-Hamiltonian for
the S ¼ 5/2 heme Fe(III) ion and contains Zeeman, axial (D),
and rhombic (E) zero-field splitting terms, respectively. The
second term is the Zeeman spin-Hamiltonian for S ¼ 1/2
CuB(II). When the exchange interaction is weak, j J j « j D j,
the axial zero-field splitting at the heme splits the Fe(III) levels
into three Kramers doublets, Ms
Fe ¼55/2,53/2 and51/2,
separated in energy by 2D and 4D, respectively. The lowest
doublet, Ms
Fe ¼ 51/2, has typical D values of 5-7 cm1.
Exchange coupling between each of these three
Kramers pairs and the single Kramers pair of CuB(II) S ¼
1/2 gives rise to three sets of states, each consisting of four
levels with the components of the lowest set characterized
by MS values of 0, 0, þ1, and 1. An excellent simulationBiophysical Journal 96(4) 1388–1398
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mode images at mid-ventricular level:
(1) Control rat, (2) DOX treatment for
12 weeks, (3) DOX plus Mito-Q treat-
ment for 12 weeks, and (4) Mito-Q treat-
ment for 12 weeks. (B) Anatomical M-
mode through the anterior and interior
walls. (C) Graph showing the radial
strain in one cardiac cycle of 6 equidis-
tant regions of the myocardium in the
short axis view. Global radial strain
was computed as the average of all six
segments.based on the weak exchange coupled model as shown in Fig. 5
(inset) was obtained using reported zero-field splitting values,
D¼ 5 cm1 andE¼ 0.03 cm1, j J j is ~1 cm1 and d¼ 5.0 A˚
(the distance between Fea3 and CuB) (39).
Fig. 6 A (signal marked Y) shows the inhibitory effects of
DOX treatment for 12 weeks on the exchange coupled tran-
sitions observed at higher powers in heart tissues. Upon
treatment with Mito-Q for 12 weeks, the broad signals due
to heme a3/CuB of CcO were partially restored in heart
tissues. However, DOX and DOX plus Mito-Q had no effect
on the EPR signals observed at g ¼ 2.015 that are character-
istic of oxidatively-inactivated iron sulfur centers (Fig. 6 B).
Effects of DOX and Mito-Q on CcO subunit
expressions
Immunoblot analysis of four subunits of CcO was performed
in heart tissues obtained from control, DOX-treated, Mito-Q-
treated, and DOX plus Mito-Q-treated rats. Fig. 7 shows the
levels of subunits I, II, IV and Va detected in total heart
homogenates. Note that there is almost constant expression
of CcO IV with time. However, the expressions of subunits
II and Va were more severely affected with nearly a 65-70%
decrease in their levels after DOX treatment for 12 weeks as
compared to controls. Administering Mito-Q to DOX-treated
rats significantly improved the expression of the CcO
subunits. However, DOX treatment for four or eight weeks
did not exhibit any significant changes in CcO on subunit
levels in heart tissues (Fig. 7).
Mito-Q inhibits DOX-mediated ﬁbrosis and
apoptosis
The cardiac tissues stained with trichrome blue showed no
apparent histological differences between control andBiophysical Journal 96(4) 1388–1398Mito-Q alone treated animals (Fig. S8). However, in the
DOX-treated animals, substantial fibrosis was observed.
The cardiac sections from animals treated with Mito-Q
plus DOX showed significantly less fibrosis compared to
the DOX group (Fig. S8). The caspase-3 activity was signif-
icantly higher in the DOX group compared to controls after
treatment with DOX for eight weeks (Fig. S9). The caspase-3
activity was diminished in the DOX plus Mito-Q group
compared to the DOX group. The complex IV activity was
determined in heart mitochondria isolated from control,
DOX-treated, and DOX plus Mito-Q-treated rats. DOX treat-
ment caused a decrease in complex IV activity by ~60%
(Fig. S9). There was no significant decrease in the complex
IV activity in rats fed with Mito-Q alone and Mito-Q signif-
icantly restored the complex IV activity in rats treated with
DOX (p < 0.05). From these results, we can conclude that
Mito-Q specifically affects the pathway by which DOX
causes a decrease in complex IV activity.
DISCUSSION
Mitochondrial dysfunction was implicated in DOX cardio-
toxicity. The exact mechanisms of DOX inhibition of mito-
chondrial electron transport and oxidative phosphorylation
are not clearly understood. Mitochondria-rich cardiac tissue
consists of many complexes, I-IV, with several metal center
proteins viz., Fe-S clusters, heme and binuclear Cu(II) and
Fe(III)-Cu(II) in their active sites. Here, we have used the
low temperature ex vivo X-band EPR to monitor the changes
in mitochondrial proteins induced by DOX during cardiomy-
opathy and cardioprotection by Mito-Q.
The EPR spectra of heart tissues obtained at liquid helium
temperatures recapitulate the evidence for exchange
coupling previously reported in isolated CcO preparations.
DOX Inhibits Cytochrome c Oxidase 1393FIGURE 4 (A) (Top) X-band EPR spectra of control
heart tissues from rats. EPR were performed at 15 K using
a 5 mW microwave power. (Bottom) Same as above but at
a higher gain. (B) Time course EPR spectra obtained from
cardiac tissues isolated from rats treated with DOX at 0, 4,
8, 10 and 12 weeks. EPR spectra were recorded at 10 K
using a 5 mW microwave power. (C) EPR signal intensities
of g ¼ 6.0 signal. Values are given as mean 5 SE.
*p<0.05 versus controls. Statistical analysis was per-
formed by using Student’s unpaired t-test.The EPR results from this study show that chronic treatment
with DOX decreased the high spin heme a3 and uncoupled
the exchange-coupled heme a3 to CuB in CcO enzyme in
rat hearts. Concomitantly, the CcO activity and the catalytic
subunit expressions (CcO II and CcO Va) were decreased.
Mito-Q restored the signal intensity of heme a3 and the
signal for coupled heme a3 and CuB of CcO in heart tissues,
as well as the heart function and CcO activity in DOX-
treated rats. These results suggest a novel mechanism
involving CcO inhibition and cardiac dysfunction during
DOX treatment.
Effect of DOX and Mito-Q on EPR spectra
of cardiac tissue
EPR spectral simulations of cardiac tissue from rats revealed
the presence of 4Fe-4S, 3Fe-4S, heme (high and low spin),
dinuclear Cu(II) and Fe(III)Cu(II) centers in the mitochon-
drial electron transport chain. A comparison of EPR spectra
of CcO from heart tissue with purified CcO (Fig. S6) revealsthat the g ¼ 6, 3, and 2.16 signals are assigned to heme a3
(high spin), heme a (low spin) and dinuclear CuA of CcO.
Upon DOX treatment, the g ¼ 6 signal initially increases
due to partial reduction of the binuclear site, Fe(III)Cu(II)
of CcO to Fe(III)Cu(I) plus the oxidized high spin signal
from cytochrome c (40). After four weeks, the g ¼ 6 signal
progressively decreased. However, the characteristic signals
due to Fe-S clusters viz., 3Fe-4S, 4Fe-4S, 2Fe-2S, heme
of complexes II and III and the nonspecific iron signal at
g ¼ 4.3 of the DOX-treated group were found to be similar
to control cardiac tissues. Thus, the active metal centers of
complexes I–III as detected by EPR were not affected by
DOX treatment in this chronic model. Mito-Q treatment
restored the g ¼ 6.0 signal intensity. The signal assigned
to cytochrome c1 (gz ¼ 3.9), cytochrome bH (gz ¼ 3.4) and
cytochrome bL (gz ¼ 3.75) of complex-III were not affected
by DOX or by DOX plus Mito-Q treatment. These results
reveal that complex III hemes and iron-sulfur clusters de-
tected by EPR were unaffected by DOX treatment in this
chronic rat model of cardiomyopathy.Biophysical Journal 96(4) 1388–1398
1394 Chandran et al.FIGURE 5 (A) Exchange coupled EPR spectra measured using high micro-
wave power, 100 mW at 10 K (solid line) experimental; (dotted line) simulated
is the sum ofB,C, andD in different proportions). (B) Simulation of exchange
interaction between Fe(III)a3 Cu(II)B in CcO using Fe(III) high spin parame-
ters,gx¼5.9,gy¼5.9,gz¼ 2.0,D¼ 5 cm1,E/D¼ 0.03 and Cu(II) gx¼ 2.06,
gy¼ 2.06, gz¼ 2.23, J¼ 1 cm1 and a distance of 5 A˚ between the Fe(III) and
Cu(II) centers. (C) Simulation of low spin heme Fe(III) using g values of heme
a of CcO and cytochrome c. (Inset) Energy level diagram for an exchange
coupled Fe(III)-Cu(II)B showing the transitions giving rise to g ¼ 2.95 and
12 resonances in EPR spectra measured at high power
jAi ¼ 1ﬃﬃﬃ
2
p
12;12


12 ; 12

Ms ¼ 0
jBi ¼ sinf
32;12

þ cosf
12; 12

Ms ¼ þ 1
jCi ¼ sinf
32 ; 12

þ cosf
12 ;12

Ms ¼ 1
jDi ¼ 1ﬃﬃﬃ
2
p
12;12


12 ; 12

Ms ¼ 0
where tan 2f ¼ (8)1/2J/(2DJ). (D) Simulation of low spin heme Fe(III)
using g values published for cytochrome bH and cytochrome bL of cyto-
chrome c reductase.Biophysical Journal 96(4) 1388–1398Effect of DOX and Mito-Q on exchange-coupled
resonances between Fea3CuB
Previous EPR results indicate that CcO with the binuclear
active center, Fea3CuB, show exchange-coupled resonances
at g ¼ 2.95 and 12 at higher microwave power (40). The
microwave power dependence on EPR signals from control,
DOX- and Mito-Q-treated cardiac tissues was similar. With
increasing microwave power, the peak intensity at g ¼ 2.95
and 12 became more pronounced. The broad resonances
observed from cardiac tissues in Fig. 5 were similar to
previous reports wherein CcO was reduced by sodium di-
thionite for 2 s (40,41). Computer simulations of exchange-
coupled EPR spectra using the reported parameters of CcO
based on the weak exchange coupling model (41,42) gave
FIGURE 6 (A) The exchange coupled EPR spectra of heart tissues ob-
tained from control rats, DOX-treated rats for 12 weeks, and DOX plus
Mito-Q-treated rats for 12 weeks. Spectra were obtained at 10K using
a microwave power of 100 mW, (solid line) experimental; (dotted line)
simulated. (B) Effect of DOX / Mito-Q on iron-sulfur cluster EPR spectra
recorded at 10 K using a 5 mW microwave power.
DOX Inhibits Cytochrome c Oxidase 1395FIGURE 7 Immunoblot analyses of
CcO subunits (I-Va) isolated from rat
hearts after 4, 8, and 12 weeks of
DOX and DOX plus Mito-Q. Experi-
mental protocols are shown in Fig. S2.a reasonably good fit. Upon DOX treatment, the intensities of
signals at g¼ 2.95 and 12 were diminished, similar to that of
the g ¼ 6 signal. At 10-12 weeks after DOX treatment, these
signals were significantly diminished. However, in the pres-
ence of Mito-Q, these signals were partially restored. The
EPR results are in agreement with the observed decrease in
the enzyme activity of CcO after a prolonged treatment with
DOX and the subsequent restoration of the CcO activity
during Mito-Q treatment.
DOX-induced suppression of CcO subunit
expressions
The complex IV of the mitochondrial respiratory chain
consists of 13 polypeptide chains (43). The three larger, cata-
lytic subunits (CcO I, CcO II, and CcO III) are encoded by
the mitochondrial DNA, and the remaining smaller subunits
(IV-VIII) are encoded by nuclear DNA (43) (Fig S10). Muta-
tions in the mitochondrial and nuclear genes encoding
polypeptides of the respiratory chain often lead to cardiomy-
opathy (44). DOX treatment was reported to inhibit the CcO
activity in cardiac tissues and leukemia cells (45). DOX
decreased the expression of mitochondrially-encoded CcO
subunits, CcO I and CcO II (46–48). In another report, over-
expression of metallothionein protein was shown to mitigate
DOX-induced cardiotoxicity (49). Cardioprotection was
accompanied by upregulation of CcO Va subunit (49). The
in vivo data show that CcO II and CcO Va subunits were
greatly diminished in heart tissues after 12 weeks of DOX
treatment (Fig. 7). There was a 25% reduction in CcO I
expression. Mito-Q administration totally restored theexpressions of CcO I, CcO II, and CcO Va. Previously, dex-
razoxane administration was reported to restore mitochon-
drial DNA-encoded CcO subunit II in DOX-treated rats
(50). As previously mentioned, both CcO subunits I and II
are mitochondrially-encoded, whereas the CcO Va is en-
coded by the nuclear DNA. This suggests that DOX-induced
cardiotoxicity may involve alterations in both mitochondrial
and nuclear genomes and that Mito-Q inhibits the oxidative
mitochondrial and nuclear DNA damage.
Alternatively, the binding of anthracyclines (daunomycin
and doxorubicin) to CcO has been reported in cancer cells
(51). In that study, the investigators suggest that CcO is
a potential target site for anthracyclines and that this interac-
tion with CcO is a plausible mechanism of DOX toxicity
(52). CcO is also the target site of the antitumor retinoid
drug, N-(4-hydroxyphenyl) retinamide (53). This chemother-
apeutic drug was shown to decrease the activity of CcO by
downregulating the CcO subunit III (53). The data presented
here (Fig. S4) show that the power saturation of low spin
heme a is affected by the addition of DOX, suggesting that
the environment surrounding heme a was altered. Our EPR
results also show that the heme a3 coupled to CuB signal
intensity in heart tissues was altered during DOX treatment
and restored by Mito-Q (Figs. 4 and 6).
CcO catalyzes the electron transfer from cytochrome c to
oxygen, forming water and creating the necessary electro-
chemical potential difference for ATP synthesis via proton
pumping. Subunit 1 of CcO contains heme a, heme a3, and
CuB. Heme a3 and CuB form a binuclear center, the site where
molecular oxygen is reduced to water. The CuA site in CcO
subunit II contains two copper atoms. Cytochrome c bindsBiophysical Journal 96(4) 1388–1398
1396 Chandran et al.to the negatively-charged region in subunit II and transfers the
electrons to CuA located in subunit II (54). Electrons from
CuA are subsequently transferred to heme a and ultimately
to the binuclear center (Fig. S10). Whether DOX binds to
the negatively-charged region of CcO subunit II (the binding
site of lysine-rich, positively-charged domain of cytochrome
c) and alters the electron distribution from cytochrome c in
CcO subunit II remains unknown. Mito-Q could compete
for the same binding site, thereby inhibiting CcO/DOX inter-
action and sustaining the electron-transport in CcO. This
hypothetical scenario is analogous to bacterial quinol
oxidases where ubiquinone/ubiquinol mediates electron-
transfer from the quinol oxidation site to the low-spin heme
B (55). The optical and EPR data obtained in a model system
consisting of DOX, hemin, and Mito-Q/hemin (Fig. S7)
suggest the interaction of DOX and Mito-Q with the heme
(Fig. S7). At present, we do not fully understand the mecha-
nism of suppression of CcO subunit expression. Previously,
CcO subunit Va was shown to play an important role in the
mitochondrial electron transfer process (49). Ongoing
research indicates that Mito-Q enhances the antitumor activity
of DOX in breast cancer cells (MCF-7 and MD-MAB-231)
but protects against DOX toxicity in rat cardiomyocytes
(H9c2). These results strongly suggest that Mito-Q is a favor-
able drug candidate for combination therapy with DOX in
breast cancer treatment (56).
In summary, we have shown here that the ex vivo low-
temperature EPR technique could be used as an effective
analytical tool to investigate the changes in the mitochondrial
heme proteins and heme centers in myocardial tissues during
DOX-induced cardiomyopathy. The EPR data indicate that
a prolonged treatment with DOX uncouples the heme
a3/CuB dinuclear active center of subunit I of CcO that is
involved in oxygen binding. In agreement with this, the
CcO activity and the expressions of CcO subunits (CcO II
and CcO Va) decreased during DOX treatment but were
largely restored by Mito-Q. Thus, our data demonstrating
selective changes to the CcO active center by DOX and
restoration of CcO subunit expressions by Mito-Q may
have mechanistic relevance in ameliorating DOX-induced
cardiotoxicity.
APPENDIX A
Modiﬁed synthesis of Mito-Q
Mito-Q was originally synthesized by Murphy and co-workers (30). As this
compound is not commercially available, we decided to synthesize it in-
house. Although we obtained several milligrams of pure Mito-Q using the
published procedures (30), the synthetic procedure was tedious and the reac-
tion yields were considerably low. We have now modified the procedure,
and with the new procedure developed in our laboratory, we can generate
pure Mito-Q in gram quantities for in vivo experiments. Fig. S1 describes
the modified procedure. The overall yield for the modified synthetic pathway
is close to 80%. We made the following modifications to the published
procedures: A major difference between our synthetic pathway of Mito-Q
(Fig. S1) and the published synthetic route lies in the synthesis of the inter-Biophysical Journal 96(4) 1388–1398mediate bromoidebenone from idebenone (steps 1 and 2). The published
route for bromoidebenone involving carbon tetrabromide and triphenyl
phosphine resulted in Mito-Q formation at a low yield that required exten-
sive purification. The proposed method (steps 1 and 2 in Fig. S1) yielded
a pure bromoidebenone derivative, and the yield is quantitative. Bromoide-
benone was used in the subsequent steps without further purification.
Because of these modifications, the overall yield of Mito-Q was 83%.
High-performance liquid chromatography analysis of Mito-Q on a C-18
column using a mixture of water and acetonitrile (gradient flow of 60-
80% at a flow-rate of 1 ml/min) showed a single peak at 14.5 min retention
time.
Experimental protocol
DOX-induced cardiomyopathy in a rat model is shown in Fig. S2.
Microwave power and temperature-dependent
EPR spectra
EPR spectra at different microwave powers ranging from 0.1 mW to 150 mW
were investigated during DOX/Mito-Q-induced alterations in structural
and magnetic interactions/surroundings around the metal spin center of
interest. The EPR relaxation behavior of high and low spin heme and
3Fe-4S signals was analyzed (see Eq. S1) and the power saturation param-
eters listed in Table S2. Typical power saturation curves obtained for low
spin heme for control heart tissue, DOX and Mito-Q treated samples are
shown in Fig. S4. The P1/2 values of high spin heme and 3Fe4S were compa-
rable in magnitude for native and DOX treated tissue samples, respectively.
This indicates that their relaxation properties did not change significantly
in the presence of DOX and DOX plus Mito-Q. However, the P1/2
values of low spin heme shows a threefold decrease as compared to the
native state.
Fig. S5 shows the temperature-dependent EPR signals due to high spin
heme (gz ¼ 6.0), 3Fe-4S cluster (gz ¼ 2.015), 4Fe-4S cluster (gz ¼ 1.95)
and low spin (gz ¼ 3.0) for control heart tissue and the DOX-treated group,
plotted as signal amplitude versus temperature. The relative peak heights
plotted for the gz ¼ 6.0 signals of control and the DOX-treated group versus
1/T give linear plots indicating that the signals obey the Curie law, (signal ¼
a/Tþ b). The temperature dependence of signal at g¼ 2.015 is typical of the
behavior of 3Fe4S clusters exhibiting high EPR signal intensity at 10 K,
diminishing to base level at ~35 K (57). Above 35 K, the residual signal re-
maining is only a small free radical at g ¼ 2.003. Inset in Fig. S5 shows the
Curie plot for control and DOX-treated samples for the signal at gz ¼ 3.0,
plotted as signal amplitude times temperature versus temperature.
Interaction between DOX or Mito-Q and hemin
Fig. S6 shows the experimental and simulated EPR spectra of CcO. Our
assignment of the EPR spectra of myocardial tissues are supported by this
data. Fig. S7, A and B support the proposal that both DOX and Mito-Q
interact with the heme as seen by the EPR spectral (Fig. S7) and optical spec-
troscopic (Fig. S7, inset) changes.
DOX-mediated ﬁbrosis and apoptosis: effect
of Mito-Q
Figs. S8 and S9 show the effects of Mito-Q on DOX-induced fibrosis and
apoptosis in cardiac tissues. As shown, Mito-Q inhibits DOX-induced
fibrosis (Fig. S8) and apoptosis (Fig. S9 A) and restores the complex IV
activity (Fig. S9 B) in heart tissues isolated from rats treated with DOX.
SUPPORTING MATERIAL
Two tables and ten figures are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(08)00128-8.
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